Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tropicamide (Ro 1-7683) is a synthetic muscarinic antagonist with actions similar to atropine and with an anticholinergic property. Upon ocular administration, tropicamide binds to and blocks the muscarinic receptors in the sphincter and ciliary muscle in the eye. This inhibits the responses from cholinergic stimulation, producing dilation of the pupil and paralysis of the ciliary muscle. Tropicamide is a diagnostic agent and is used to produce short-duration mydriasis and cycloplegia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | In stock | $ 48.00 | |
500 mg | In stock | $ 81.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 50.00 |
Description | Tropicamide (Ro 1-7683) is a synthetic muscarinic antagonist with actions similar to atropine and with an anticholinergic property. Upon ocular administration, tropicamide binds to and blocks the muscarinic receptors in the sphincter and ciliary muscle in the eye. This inhibits the responses from cholinergic stimulation, producing dilation of the pupil and paralysis of the ciliary muscle. Tropicamide is a diagnostic agent and is used to produce short-duration mydriasis and cycloplegia. |
Targets&IC50 | M4 mAChR:8 nM |
In vitro | At a concentration of 0.5%, Nepafenac significantly inhibits (46%) the breakdown of the blood-retinal barrier, leading to a 65% reduction in retinal edema, and almost completely suppresses PGE2 synthesis (96%). Nepafenac's bioavailability in ocular tissue is notably higher. Its inhibitory action on COX-1 is weaker (IC50: 64.3 μM). In rabbits, Nepafenac inhibits prostaglandin synthesis within the retina/choroid (55%) and in the iris/ciliary body (85-95%). Compared to control mice, Nepafenac substantially reduces choroidal neovascularization and ischemia-induced retinal neovascularization and also slows the increase in ischemia-induced retinal VEGF mRNA expression. In ocular and metastatic animal models, Nepafenac delays the progression of malignant tumors and decreases the weight of choroidal melanoma. In retinal microvessels of diabetic rats with insulin deficiency, Nepafenac markedly suppresses retinal prostaglandin E (2), superoxide, cyclooxygenase-2, and leukostasis, but does not affect vascular endothelial growth factor and nitric oxide. In diabetic rats, the compound significantly inhibits the number of dUTP nick end labeling (TUNEL) positive capillary cells, pericytes, and acellular capillaries mediated by transferase. |
Synonyms | Ro 1-7683 |
Molecular Weight | 284.35 |
Formula | C17H20N2O2 |
CAS No. | 1508-75-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 53 mg/mL (186.4 mM)
Ethanol: 53 mg/mL (186.4 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tropicamide 1508-75-4 Neuroscience AChR Ro 1-7683 dilation acetylcholine Inhibitor muscarinic inhibit pupil cycloplegia mAChR mydriasis Muscarinic acetylcholine receptor inhibitor